Dose-dependent reduction of 50% clot lysis time in the presence of MA-TCK26D6 in human plasma with 1nM exogenous thrombomodulin (■) or without additional thrombomodulin (●). Clot lysis times are expressed as percentages relative to reduction of clot lysis time by PTCI (4.76μM).